Incidence of any hypoglycaemia (defined as plasma glucose ≤3.9 mmol/l) with tirzepatide did not differ vs placebo (ESM Fig. 3) and was lower with tirzepatide compared with basal insulin (OR ranging from 0.17 with tirzepatide 5 mg to 0.25 with tirzepatide 15 mg) (ESM Fig. 4). Here, INS is linked to Hypoglycemia.